Loading…
← CockpitCompetitor Analysis › 2637.HK Fujian Haixi Pharmaceuticals Co., Ltd. Class HOpen in the cockpit ↗

Fujian Haixi Pharmaceuticals Co., Ltd. Class H2637.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Biotechnology

Fujian-based Chinese pharmaceutical maker, per its industry classification; specific product portfolio not independently confirmed.

Momentum weak 28
Mkt cap
$1.47B
US dollars, full cap
Free float
15%
of shares outstanding
$/day
$888,593
20-day average traded
Fwd P/E
46.4×
forward earnings
ROIC−WACC
n/a
WACC 10.1%
Hurdle
n/a
no reverse DCF
Close · HKDHK$148.80
1D+4.1%
1W-6.9%
1M-1.4%
3M-31.4%
6M-32.3%
YTD+9.4%
1Y+21.2%
ATR %5.6%
52w lowhigh50.8% off high

What Fujian Haixi Pharmaceuticals does

Fujian-based Chinese pharmaceutical maker, per its industry classification; specific product portfolio not independently confirmed.

Where it sits in the supply chain

  • Pharmaceuticals
  • Drug manufacturing & distribution

Moat: none

Headquarters: Fujian, China · Employees: 200

Fujian Haixi Pharmaceuticals at a glance

Size Fujian Haixi Pharmaceuticals (2637.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $1.47B, the 481st largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$148.80 on 18 Nov 2026.

Performance Over six months the shares fell 32.3%, against -14.1% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 6th lowest of 20 in its peer set.

Growth Revenue grew 24.8% over the last twelve months (peer median +28.0%); the operating margin is 33.0% (peer median -56.7%).

Valuation It trades at 46.4× forward earnings against a peer median of 16.7× (3rd most expensive of 6).

Relative performance

7510012521 May 202621 Aug 202618 Nov 2026Peer median 852637.HK 63
Six months, rebased to 100: Fujian Haixi Pharmaceuticals against the median of its 20 peers (local-currency closes).

Fujian Haixi Pharmaceuticals financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenuen/aHK$632MHK$506MHK$350MHK$247M
Revenue growth—+25%+45%+42%—
Gross profitn/aHK$527MHK$415MHK$291MHK$200M
EBITDAn/aHK$217MHK$149MHK$136MHK$96.5M
Net incomen/aHK$192MHK$148MHK$130MHK$80.2M
Free cash flown/aHK$109M-HK$30.4MHK$85.6MHK$45.3M
Capital expendituren/aHK$48.7MHK$194MHK$65.7MHK$36.9M
Total debtn/aHK$123MHK$71.2MHK$55.1MHK$103M

Quarterly statements and history in the cockpit →

Fujian Haixi Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%-50%0%+50%URGN688765MSB087010IMCR688319688105KRSAABSIPGENANABNRIXRAPP68818545882637.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Fujian Haixi Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

0%+1,000%+2,000%0×100×200×URGN688105PGENANAB6881852637.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Fujian Haixi Pharmaceuticals is the large dot.

Fujian Haixi Pharmaceuticals competitors and peer comparison

How Fujian Haixi Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Fujian Haixi Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
Measure2637.HKPeer medianRank in peer set
1-month return-1.4%-14.8%5th highest of 21
6-month return-32.3%-14.1%6th lowest of 20
Distance from 52-week high-50.8%-44.6%7th lowest of 21
Revenue growth (TTM)+24.8%+28.0%9th lowest of 18
Operating margin33.0%-56.7%3rd highest of 19
Forward P/E46.4×16.7×3rd most expensive of 6
Net debt / EBITDA-6.3×0.9×least indebted of 4

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Fujian Haixi Pharmaceuticals 2637.HKHong Kong$1.47B-32%+25%33%46.4×n/an/a
UroGen Pharma URGNUnited States$1.46B-1%+159%-12%16.7×n/an/a
Wuhan Healthgen Biotechnology 688765.SSChina$1.46B-51%+90%-297%n/an/an/a
Mesoblast MSB.AXAustralia$1.49B-17%+556%-43%n/an/an/a
Peptron 087010.KSSouth Korea$1.49B-68%-13%-488%n/an/an/a
Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCRUnited States$1.44B-7%+13%-7%n/an/an/a
TLC BioSciences 7924.TWOTaiwan$1.50Bn/an/an/an/an/an/a
Chengdu Olymvax Biopharmaceuticals 688319.SSChina$1.51B-37%+12%8%n/an/an/a
Nanjing Vazyme Biotech 688105.SSChina$1.42B+25%+16%-5%137.8×39.4%-2.5%
uniQure QUREUnited States$1.42B-17%+28%-1,027%n/an/an/a
Korsana Biosciences KRSAUnited States$1.52B+54%-64%-5,277%n/an/an/a
Absci ABSIUnited States$1.41B+65%-47%-9,155%n/an/an/a
Kailera Therapeutics KLRAUnited States$1.53B-41%n/an/an/an/an/a
Precigen PGENUnited States$1.53B0%+2,388%21%7.3×n/an/a
AnaptysBio ANABUnited States$1.40B-22%+13%62%4.9×0.5%+25.6%
Nurix Therapeutics NRIXUnited States$1.54B-14%+739%41%n/an/an/a
Rapport Therapeutics RAPPUnited States$1.39B-34%n/a-838%n/an/an/a
CanSino Biologics 688185.SSChina$1.38B0%+30%-4%199.3×n/an/a
Vir Biotechnology VIRUnited States$1.57B+3%+1,696%-70%n/an/an/a
Oncolys BioPharma 4588.TJapan$1.37B+181%+1,749%-295%n/an/an/a
Intellia Therapeutics NTLAUnited States$1.37B-20%-8%-821%n/an/an/a

Questions

Which companies are Fujian Haixi Pharmaceuticals's closest peers?
The cockpit's peer set: UroGen Pharma (URGN), Wuhan Healthgen Biotechnology (688765.SS), Mesoblast (MSB.AX), Peptron (087010.KS), Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh (IMCR), TLC BioSciences (7924.TWO), Chengdu Olymvax Biopharmaceuticals (688319.SS), Nanjing Vazyme Biotech (688105.SS).
Is Fujian Haixi Pharmaceuticals expensive compared with its peers?
On forward p/e it trades at 46.4× against a peer median of 16.7×, 3rd most expensive of 6 in its peer set.
How has Fujian Haixi Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned -32.3% against -14.1% for the median peer; over one year +21.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.